iBio Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Investments in Debt Securities

Investments in Debt Securities

9 Months Ended

Mar. 31, 2023

Investments in Debt and Equity Securities [Abstract]

8. Investments in Debt Securities

The Company did not hold any investments in debt securities at March 31, 2023. The components of investments in debt securities are as follows (in thousands):


	March 31,		June 30,
	2023		2022
Adjusted cost	$	—	$	11,029
Gross unrealized losses		—		(184)
Fair value	$	—	$	10,845

The fair value of available-for-sale debt securities, by contractual maturity, was as follows (in thousands):


	March 31,		June 30,
Fiscal period ending:	2023		2022
2023	$	—	$	8,054
2024		—		2,791
	$	—	$	10,845

Amortization of premiums paid on the debt securities amounted to $7,000 and $74,000 for the three months ended March 31, 2023 and 2022, respectively, and $67,000 and $269,000 for the nine months ended March 31, 2023 and 2022, respectively.

Realized gains on available-for-sale debt securities are as follows (in thousands):


	Three Months Ended		Three Months Ended
	March 31,		March 31,
	2023		2022
Proceeds from sale of debt securities	$	5,943	$	—
Cost of debt securities		6,036		—
Realized loss on sale of debt securities	$	(93)	$	—


	Nine Months Ended		Nine Months Ended
	March 31,		March 31,
	2023		2022
Proceeds from sale of debt securities	$	6,739	$	—
Cost of debt securities		6,837		—
Realized loss on sale of debt securities	$	(98)	$	—